JP Morgan Chase’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-164,055
| Closed | -$740K | – | 7763 |
|
|
2025
Q2 | $740K | Sell |
164,055
-83,387
| -34% | -$375K | ﹤0.01% | 4559 |
|
|
2025
Q1 | $1.1M | Buy |
247,442
+149,782
| +153% | +$870K | ﹤0.01% | 4274 |
|
|
2024
Q4 | $765K | Buy |
97,660
+67,325
| +222% | +$820K | ﹤0.01% | 4803 |
|
|
2024
Q3 | $399K | Buy |
30,335
+2,854
| +10% | +$36.2K | ﹤0.01% | 5055 |
|
|
2024
Q2 | $332K | Sell |
27,481
-3,687
| -12% | -$49.8K | ﹤0.01% | 4899 |
|
|
2024
Q1 | $507K | Sell |
31,168
-10,196
| -25% | -$137K | ﹤0.01% | 4786 |
|
|
2023
Q4 | $282K | Buy |
41,364
+8,841
| +27% | +$51.1K | ﹤0.01% | 5145 |
|
|
2023
Q3 | $177K | Sell |
32,523
-6,000
| -16% | -$34.9K | ﹤0.01% | 5135 |
|
|
2023
Q2 | $262K | Sell |
38,523
-156,912
| -80% | -$1.18M | ﹤0.01% | 4917 |
|
|
2023
Q1 | $979K | Buy |
195,435
+162,752
| +498% | +$665K | ﹤0.01% | 4066 |
|
|
2022
Q4 | $160K | Sell |
32,683
-1,296
| -4% | -$9.41K | ﹤0.01% | 5145 |
|
|
2022
Q3 | $491K | Buy |
33,979
+1,315
| +4% | +$21.8K | ﹤0.01% | 4483 |
|
|
2022
Q2 | $494K | Sell |
32,664
-9,658
| -23% | -$113K | ﹤0.01% | 4561 |
|
|
2022
Q1 | $503K | Buy |
42,322
+4,752
| +13% | +$48.8K | ﹤0.01% | 4690 |
|
|
2021
Q4 | $610K | Buy |
37,570
+1,690
| +5% | +$36.1K | ﹤0.01% | 4703 |
|
|
2021
Q3 | $1.02M | Buy |
35,880
+461
| +1% | +$14.5K | ﹤0.01% | 4290 |
|
|
2021
Q2 | $1.2M | Buy |
35,419
+3,503
| +11% | +$112K | ﹤0.01% | 4178 |
|
|
2021
Q1 | $965K | Buy |
31,916
+1,909
| +6% | +$78.3K | ﹤0.01% | 4261 |
|
|
2020
Q4 | $1.49M | Buy |
30,007
+325
| +1% | +$15K | ﹤0.01% | 3701 |
|
|
2020
Q3 | $1.2M | Sell |
29,682
-1,754
| -6% | -$69.8K | ﹤0.01% | 3547 |
|
|
2020
Q2 | $1.36M | Sell |
31,436
-1,035
| -3% | -$39.1K | ﹤0.01% | 3335 |
|
|
2020
Q1 | $847K | Sell |
32,471
-1,762
| -5% | -$51.2K | ﹤0.01% | 3503 |
|
|
2019
Q4 | $1.07M | Sell |
34,233
-963
| -3% | -$28.5K | ﹤0.01% | 3806 |
|
|
2019
Q3 | $917K | Buy |
35,196
+2,007
| +6% | +$51.3K | ﹤0.01% | 3885 |
|
|
2019
Q2 | $739K | Buy |
33,189
+3,115
| +10% | +$71.5K | ﹤0.01% | 4028 |
|
|
2019
Q1 | $788K | Sell |
30,074
-1,249
| -4% | -$27.4K | ﹤0.01% | 3948 |
|
|
2018
Q4 | $637K | Buy |
31,323
+1,298
| +4% | +$29.8K | ﹤0.01% | 4008 |
|
|
2018
Q3 | $798K | Buy |
+30,025
| New | +$763K | ﹤0.01% | 4041 |
|
Other funds holding YMAB
JP Morgan Chase's YMAB Position: Q3 2025 in Review
JP Morgan Chase sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 164,055 shares — an estimated $740K sold.
JP Morgan Chase first reported a position in YMAB in Q3 2018 and held it in 28 quarters. The position peaked at $1.49M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- JP Morgan Chase reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- JP Morgan Chase sold 164,055 Y-mAbs Therapeutics shares in Q3 2025, an estimated $740K.
- JP Morgan Chase first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 28 quarters.
- JP Morgan Chase's Y-mAbs Therapeutics position peaked at $1.49M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.